FDA Approves J&J's IMAAVY as First Treatment for Rare Anemia
JNJ sits 56% above its 52-week low of $173.33.
Summary
The FDA approved IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia (wAIHA), making it the first therapy specifically indicated for this rare, life-threatening condition. Approval covers adults and pediatric patients 12+ who are on or have received corticosteroids. The Phase 2/3 ENERGY study showed about three times as many patients achieved durable hemoglobin response versus placebo, with a mean Hgb increase of 1g/dL at Week 1 and a 3.5-point higher fatigue score at Week 24. This expands IMAAVY's label beyond its April 2025 approval for generalized myasthenia gravis, strengthening J&J's rare disease portfolio. The approval follows a Priority Review and adds a new revenue stream in an underserved market with no targeted therapies. J&J shares were down 0.33% premarket at $270.81, near the 52-week high of $276.47.
At the time of this announcement, JNJ was trading at $271.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $658B. The 52-week trading range was $173.33 to $276.47. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.